SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Heymann D, Rousselle AV 2000 gp130 Cytokine family and bone cells. Cytokine 12: 14551468.
  • 2
    Girasole G, Jilka RL, Passeri G, Boswell S, Boder G, Williams DC, Manolagas SC 1992 17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: A potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest 89: 883891.
  • 3
    Littlewood AJ, Russell J, Harvey GR, Hughes DE, Russell RG, Gowen M 1991 The modulation of the expression of IL-6 and its receptor in human osteoblasts in vitro. Endocrinology 129: 15131520.
  • 4
    Ishimi Y, Miyaura C, Jin CH, Akatsu T, Abe E, Nakamura Y, Yamaguchi A, Yoshiki S, Matsuda T, Hirano T 1990 IL-6 is produced by osteoblasts and induces bone resorption. J Immunol 145: 32973303.
  • 5
    Romas E, Udagawa N, Zhou H, Tamura T, Saito M, Taga T, Hilton DJ, Suda T, Ng KW, Martin TJ 1996 The role of gp130-mediated signals in osteoclast development: Regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures. J Exp Med 183: 25812591.
  • 6
    Udagawa N, Takahashi N, Katagiri T, Tamura T, Wada S, Findlay DM, Martin TJ, Hirota H, Taga T, Kishimoto T 1995 Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J Exp Med 182: 14611468.
  • 7
    Horwood NJ, Elliott J, Martin TJ, Gillespie MT 1998 Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 139: 47434746.
  • 8
    Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, Athanasou NA 2003 Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 32: 17.
  • 9
    Salmassi A, Lu S, Hedderich J, Oettinghaus C, Jonat W, Mettler L 2001 Interaction of interleukin-6 on human granulosa cell steroid secretion. J Endocrinol 170: 471478.
  • 10
    Branisteanu I, Pijnenborg R, Spiessens C, Van der Auwera I, Keith JC Jr, Van Assche FA 1997 Detection of immunoreactive interleukin-11 in human follicular fluid: Correlations with ovarian steroid, insulin-like growth factor I levels, and follicular maturity. Fertil Steril 67: 10541058.
  • 11
    Cheleuitte D, Mizuno S, Glowacki J 1998 In vitro secretion of cytokines by human bone marrow: Effects of age and estrogen status. J Clin Endocrinol Metab 83: 20432051.
  • 12
    Girasole G, Passeri G, Jilka RL, Manolagas SC 1994 Interleukin-11: A new cytokine critical for osteoclast development. J Clin Invest 93: 15161524.
  • 13
    Verhaeghe J, Van Herck E, van Bree R, Bouillon R, Dequeker J, Keith JC Jr 1998 Recombinant human interleukin-11 does not modify biochemical parameters of bone remodeling and bone mineral density in adult ovariectomized rats. J Interferon Cytokine Res 18: 4953.
  • 14
    Shaughnessy SG, Walton KJ, Deschamps P, Butcher M, Beaudin SM 2002 Neutralization of interleukin-11 activity decreases osteoclast formation and increases cancellous bone volume in ovariectomized mice. Cytokine 20: 7885.
  • 15
    Kimble RB, Bain S, Pacifici R 1997 The functional block of TNF but not of IL-6 prevents bone loss in ovariectomized mice. J Bone Miner Res 12: 935941.
  • 16
    Menaa C, Reddy SV, Kurihara N, Maeda H, Anderson D, Cundy T, Cornish J, Singer FR, Bruder JM, Roodman GD 2000 Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone. J Clin Invest 105: 18331838.
  • 17
    Nakchbandi IA, Mitnick MA, Lang R, Gundberg C, Kinder B, Insogna K 2002 Circulating levels of interleukin-6 soluble receptor predict rates of bone loss in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 87: 49464951.
  • 18
    Nowell MA, Richards PJ, Horiuchi S, Yamamoto N, Rose-John S, Topley N, Williams AS, Jones SA 2003 Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: Blockade of arthritis severity by soluble glycoprotein 130. J Immunol 171: 32023209.
  • 19
    Suda T, Udagawa N, Nakamura I, Miyaura C, Takahashi N 1995 Modulation of osteoclast differentiation by local factors. Bone 17: 87S91S.
  • 20
    Poli V, Balena R, Fattori E, Markatos A, Yamamoto M, Tanaka H, Ciliberto G, Rodan GA, Costantini F 1994 Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 13: 11891196.
  • 21
    Dahmen H, Horsten U, Kuster A, Jacques Y, Minvielle S, Kerr IM, Ciliberto G, Paonessa G, Heinrich PC, Muller-Newen G 1998 Activation of the signal transducer gp130 by interleukin-11 and interleukin-6 is mediated by similar molecular interactions. Biochem J 331: 695702.
  • 22
    Kishimoto T, Taga T, Akira S 1994 Cytokine signal transduction. Cell 76: 253262.
  • 23
    Sims NA, Jenkins BJ, Quinn JM, Nakamura A, Glatt M, Gillespie MT, Ernst M, Martin TJ 2004 Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. J Clin Invest 113: 379389.
  • 24
    Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, Zinkernagel R, Bluethmann H, Kohler G 1994 Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368: 339342.
  • 25
    Robb L, Li R, Hartley L, Nandurkar HH, Koentgen F, Begley CG 1998 Infertility in female mice lacking the receptor for interleukin 11 is due to a defective uterine response to implantation. Nat Med 4: 303308.
  • 26
    Nandurkar HH, Robb L, Tarlinton D, Barnett L, Kontgen F, Begley CG 1997 Adult mice with targeted mutation of the interleukin-11 receptor (IL11Ra) display normal hematopoiesis. Blood 90: 21482159.
  • 27
    Sims NA, Clement-Lacroix P, Da Ponte F, Bouali Y, Binart N, Moriggl R, Goffin V, Coschigano K, Gaillard-Kelly M, Kopchick J, Baron R, Kelly PA 2000 Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I but independent of Stat5. J Clin Invest 106: 10951103.
  • 28
    Horn D, Rivas P, McCluskey B, Mundy GR, Gutierrez G 2002 A new staining technique for undecalcified bone sections that enhances visualization of fluorochromes. J Bone Miner Res 17: S416.
  • 29
    Quinn JM, Whitty GA, Byrne RJ, Gillespie MT, Hamilton JA 2002 The generation of highly enriched osteoclast-lineage cell populations. Bone 30: 164170.
  • 30
    Lam J, Nelson CA, Ross FP, Teitelbaum SL, Fremont DH 2001 Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. J Clin Invest 108: 971979.
  • 31
    Montero A, Okada Y, Tomita M, Ito M, Tsurukami H, Nakamura T, Doetschman T, Coffin JD, Hurley MM 2000 Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation. J Clin Invest 105: 10851093.
  • 32
    Sabatakos G, Sims NA, Chen J, Aoki K, Kelz MB, Amling M, Bouali Y, Mukhopadhyay K, Ford K, Nestler EJ, Baron R 2000 Overexpression of DeltaFosB transcription factor(s) increases bone formation and inhibits adipogenesis. Nat Med 6: 985990.
  • 33
    Sims NA, Clement-Lacroix P, Minet D, Fraslon-Vanhulle C, Gaillard-Kelly M, Resche-Rigon M, Baron R 2003 A functional androgen receptor is not sufficient to allow estradiol to protect bone after gonadectomy in estradiol receptor-deficient mice. J Clin Invest 111: 13191327.
  • 34
    Sims NA, Dupont S, Krust A, Clement-Lacroix P, Minet D, Resche-Rigon M, Gaillard-Kelly M, Baron R 2002 Deletion of estrogen receptors reveals a regulatory role for estrogen receptors-beta in bone remodeling in females but not in males. Bone 30: 1825.
  • 35
    Calvi LM, Sims NA, Hunzelman JL, Knight MC, Giovannetti A, Saxton JM, Kronenberg HM, Baron R, Schipani E 2001 Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. J Clin Invest 107: 277286.
  • 36
    Gimble JM, Wanker F, Wang CS, Bass H, Wu X, Kelly K, Yancopoulos GD, Hill MR 1994 Regulation of bone marrow stromal cell differentiation by cytokines whose receptors share the gp130 protein. J Cell Biochem 54: 122133.
  • 37
    Keller DC, Du XX, Srour EF, Hoffman R, Williams DA 1993 Interleukin-11 inhibits adipogenesis and stimulates myelopoiesis in human long-term marrow cultures. Blood 82: 14281435.
  • 38
    Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y, Koishihara Y, Ohsugi Y, Kumaki K, Taga T, Kishimoto T, Suda T 1993 Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 90: 1192411928.
  • 39
    O'Brien CA, Gubrij I, Lin SC, Saylors RL, Manolagas SC 1999 STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone. J Biol Chem 274: 1930119308.
  • 40
    Quinn JM, Nakamura A, Jenkins B, Sims NA, Ernst M, Martin TJ, Gillespie MT 2003 Tyrosine-757 of gp130 plays a critical role in osteoclast formation. J Bone Miner Res 18: S233.
  • 41
    Takeuchi Y, Watanabe S, Ishii G, Takeda S, Nakayama K, Fukumoto S, Kaneta Y, Inoue D, Matsumoto T, Harigaya K, Fujita T 2002 Interleukin-11 as a stimulatory factor for bone formation prevents bone loss with advancing age in mice. J Biol Chem 277: 4901149018.
  • 42
    Ogata N, Chikazu D, Kubota N, Terauchi Y, Tobe K, Azuma Y, Ohta T, Kadowaki T, Nakamura K, Kawaguchi H 2000 Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover. J Clin Invest 105: 935943.